Aclarion Inc (ACON)

[subslover]

Never holds its gains so you are spot on!

[cottonmather]

We'll see. Have an order in.

[TommyBoyTrader9460]

$ACON
https://x.com/hannahadad8890/status/1737423187359514858?s=61

[Invest-in-America]

ACON: "SPECTROSCOPY SYSTEM FOR DIAGNOSING PAINFUL AND NON-PAINFUL INTERVERTEBRAL DISCS".

Heck, rather than all of THAT techno-complexity, why doesn't the Doctor or Nurse simple ASK the patient!!! To wit, "Is your lower back PAINFUL, or NOT PAINFUL?"


"Now Homer, is your fucked-up spine PAINFUL, or NOT PAINFUL?? Now our newly-Patented newfangled MR gadget here can itself DETECT that, but I would like to hear it from YOU, Dude. So we can be ABSOLUTELY certain that you are in fact suffering PAIN."

[Zorro]

ACON So they have some shares to sell

[Invest-in-America]

ACON: But just blew-out an engine.

[subslover]

It's a rocket ship!!!!!! WOW

[TheFinalCD]

https://finviz.com/quote.ashx?t=ACON&p=d

https://dilutiontracker.com/app/search/ACON


PATENT NEWS

$ACON Granted US Patent #11844601 Today For "MR SPECTROSCOPY SYSTEM FOR DIAGNOSING PAINFUL AND NON-PAINFUL INTERVERTEBRAL DISCS (SEVERE LOW BACK PAIN)".https://t.co/wmKOvqJdy2 pic.twitter.com/POmpyDLLR8

— Patent_Stocks (@US_Patent_Plays) December 19, 2023

S-1 CAUTION

$ACON S-1 doesn't scare anyone anymore😂
Brave new world!

— Biosmallcap (@RachitJ3) December 19, 2023

[Nealio]

The 12M dilution looks to be done as well as possible...and for this type of company...still in development of health tech, this is normal to raise capital for some years. They were paid $10M for the 12M shares by the brokerage; that means they sold the shares for approx 0.80, I'll drop it some from .83 since there must be other costs. That is a decent deal, considering the shares were much lower...probably due to the doubt of what price they would be given for the shares. I owned the stock before in the low $1's. Glad I got out after a swing trade. I'm looking to buy in if I can find a good price...seems value is near $0.80-1.00. Thoughts? Am I not aware of some other factor...any upcoming catalysts anyone knows about?

[Monksdream]

ACON new 52 week low

[Monksdream]

ACON new 52 week low

[subslover]

This dog never holds its gains. Back to sub $1.00 tomorrow imo.

[TheFinalCD]

1.64-1.15

It's a dog with fleas! LOL

[subslover]

Nociscan cost-effectiveness abstract highlights dominance over provocative discography and can save the US healthcare system $283M to $441M annually.

The International Society for the Advancement of Spine Surgery (ISASS) Annual Meeting was held June 1-3, 2023.

ISASS Policy Statement on Lumbar Spinal Fusion Surgery acknowledges MR Spectroscopy as an effective alternative to provocative discography.

BROOMFIELD, CO - (NewMediaWire) - June 08, 2023 - Aclarion, Inc., ("Aclarion" or the "Company") (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today their Nociscan cost-effectiveness abstract was presented at the International Society for the Advancement of Spine Surgery on Saturday, June 3, 2023. The cost-effectiveness study comparing Nociscan to provocative discography was performed at the Center for Disruptive Musculoskeletal Innovations (CDMI) through a National Science Foundation (NSF) grant sponsored by Aclarion. The abstract highlights that Nociscan statistically dominates provocative discography (PD) because PD is both more costly and less effective.

"An evidence-based process for accurate identification of a source for low back pain is valuable to improve cost-effectiveness of operative and non-operative management strategies," said Leslie Wilson, PhD, Professor in the Department of Medicine and the Department of Clinical Pharmacy at University of California San Francisco. "The economic model includes a decision-tree comparing Nociscan with PD based on a comprehensive set of peer-reviewed data. The incremental cost-effectiveness ratio (ICER) confirms that Nociscan statistically dominates PD, with a Monte Carlo sensitivity analysis illustrating Nociscan dominates over a wide willingness-to-pay range. In total, Nociscan can save the US healthcare system from $283M to $441M annually."

Chronic low back pain (cLBP) is a global healthcare problem, with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. Conventional imaging and diagnostics provide valuable structural information but struggle to identify the source of the pathogenic pain. Low surgical success rates (41-57%)1,2 are common especially for patients suffering from Discogenic Chronic Low Back Pain (DCLP).

"We are pleased with the cost-effectiveness abstract results," said Ryan Bond, Chief Strategy Officer at Aclarion. "We believe the results illustrating Nociscan's outperformance over provocative discography will be important to our physician customers and their patients, but will also speak clearly to the payer community, who are constantly challenged to reconcile the health outcomes achieved for the dollars they spend; the value in healthcare."

Aclarion will be attending the American Society for Pain & Neuroscience (ASPN), July 13-16, 2023 in Miami, FL where their health economics outcomes Abstract will be highlighted. For information about ASPN 2023, please visit: https://aspnpain.com/aspn-annual-conference-july-2023/

1. Wei J, Song Y, et al. Comparison of artificial total disc replacement versus fusion for lumbar disc disease: a meta-anaylsis of randomized controlled trials. Int Orthop. 2013; 37(7):1315-1325

Ibrahim T, Tieyjeh IM, et al. Surgical versus nonsurgical treatment of chronic low back pain: a meta-analysis of randomized trials. Int Orthop. 2008; 32(1):107-113
About Aclarion, Inc.

Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy ("MRS"), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company's current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes" and "expects" or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company's current plans and expectations, as well as future results of operations and financial condition. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2022, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contacts:

Kirin M. Smith

PCG Advisory, Inc.

646.823.8656

[e-mail]



Media Contacts:

[Triple nickle]

1.64 top and drop

[subslover]

It's a dog with fleas! LOL

[TheFinalCD]

ACON SUBdollar

Classic GAP & TRAP

[subslover]

That is precisely the case! The most extensive POS stocks make these incredible high runs. It's just like playing craps buddy. I follow the hot guy with the dice and win every hand. Go to a large casino and you will find one. AMAZING!

[TheFinalCD]

IMO WE HAVE TO ACT LIKE NEWBIES AND JUST TRADE THESE WHEN THEY HAVE VOLUME AND MOMENTUM

IF WE USE OUR EXTENSIVE EXPERIENCE WE USUALLY PASS ON THEM AND JUST MISS OPPORTUNITIES FOR GAINS

I KNOW BECAUSE I WAS TOO WISE AND PASSED ON MANY RUNNERS, BECAUSE I SAID THEY WERE CRAP AND NEWS WAS LIGHT & FLUFFY LOL

DIFFERENT MARKETS NOW AFTER 2020

[TheFinalCD]

ACON 1.50'S NEW HIGHS

[Triple nickle]

Yup wild to say the least

[TheFinalCD]

YEP WILD MARKETS

[subslover]

I LOL when I read the PR because it's so fluffy and yet shares exploded. Nothing surprises me anymore

[TheFinalCD]

ACON NEWS https://finance.yahoo.com/news/aclarion-announces-engagement-london-clinic-113000037.html

https://finviz.com/quote.ashx?t=ACON&ty=c&ta=1&p=d

[madras50]

so why did this just sht the bed from 2.50 + to .70?

[subslover]

Yup! Looks like it will reopen in the $2.30 range!

[Nealio]

Halted again AFAICT...my streamer shows 00s bid/ask

[subslover]

At least 3x's, The MMs needed to offer much higher to find sellers!

[Nealio]

2.13 now...very nice! says 22M shares

[Nealio]

ACON ipo'd in May 22...is that right?
Stock has never been this high? Anyone know ipo price?
I had a sell order from weeks back at 1.73...but now I think it's oging higher. Any targets?

[Nealio]

Halted several times...anyone know exactly how many? I'm not good at reading this chart-
https://www.nasdaqtrader.com/Trader.aspx?id=TradeHalts

[subslover]

Halted. As of February 27, 2023, 7,861,515 shares of the registrant’s common stock was outstanding

[Jayzp]

Ther buy now with cancer good news

THER MEME STOCK

https://www.prnewswire.com/news-releases/theralink-acquires-exclusive-landmark-immunotherapy-patent-including-biomarker-from-vanderbilt-university-301787847.html

[subslover]

Beautiful news!

[tw0122]

Bust $1.10 then $1.30 next level to watch

via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today the publication of two-year durability data which demonstrates improved surgical outcomes for discogenic low back pain (DLBP) surgeries at chemically painful lumbar discs identified by Nociscan.
The multi-year, single site clinical trial comprised 78 patients who received surgery for DLBP following standard clinical work-up including MRI and provocative discography. Nociscan was performed on all patients but was not available in the surgical decision-making process. The patient outcomes were evaluated using the Oswestry Disability Index (ODI) scoring scale (100 points), a common clinical outcomes measure for low back pain, where surgical success was defined using an industry-standard improvement of 15 points or more between surgeries that were concordant versus discordant with Nociscan results. Surgical success rates at 2 years illustrates a 22 percentage point improvement (p = 0.07) between the two groups. The results suggest that Nociscan provides valuable new information that can help physicians successfully treat DLBP.

Matthew Gornet, MD, orthopedic surgeon and lead author, stated, “The two-year surgical outcomes of the clinical trial are significantly clear on the primary (ODI) endpoint. I believe Nociscan is something that will accurately help all physicians treating chronic low back pain, and I believe it can change the standard of care. I feel uncomfortable now moving forward in treatment of low back pain patients without the information Nociscan provides, like a cardiologist who does not have an echocardiogram.” Dr. Gornet is a fellowship-trained spine surgeon, accomplished author, and national leader in treating patients with chronic low back pain.

Chronic low back pain (cLBP) is a global healthcare problem with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. “For decades, the source of low back pain has been difficult to precisely identify. Provocative discography is an effective diagnostic tool for discogenic pain, but it is invasive, painful, expensive, and unfavorable with patients. MRI has become a standard diagnostic for back pain, but MRI cannot differentiate between discs that are painful and those that are merely aging. Nociscan objectively measures pain biomarkers in an MRI-like experience, without the negative attributes of discography,” said Ryan Bond, Chief Strategy Officer at Aclarion.

"The durability of the 2-year outcomes is a hallmark achievement. These important results will serve as the cornerstone of Aclarion’s on-going commitment to leading with clinical evidence and changing the standard of care for low back pain. In addition, the Economic Value Analysis of Low back pain (EVAL) abstract, a healthcare economics study completed by CDMI illustrating dominant economic and clinical benefits for Nociscan, has been submitted for presentation at upcoming spine society meetings. Aclarion is moving forward with additional clinical trials, which collectively will expand on the impressive foundational evidence compiled by Dr. Gornet and team,” said Brent Ness, CEO at Aclarion.

“The two year durable results of the Gornet Trial, published in the reputable European Spine Journal, add to the mounting evidence supporting the logical conclusion that knowing the source of pain enables better treatment planning and eventual outcomes,” stated Robert Eastlack, MD, Head of the Division of Spine Surgery at Scripps Clinic in San Diego, CA. “The fact that this is a surgical outcome trial, not just a comparison to the accuracy of other existing diagnostic tools, bolsters my confidence in using Nociscan in my practice.”

Access to publication can be found here: https://pubmed.ncbi.nlm.nih.gov/37014434/

Aclarion will be hosting a company symposium at SPINEWEEK 2023, May 1-5. For more information about SPINEWEEK 2023, please visit: www.spineweek.org

About Aclarion, Inc.

Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.

[Nealio]

ACON- great buy here. bumping this group up! Should run over $1 near term...higher in 2023 fiscal.

[DNORWOOD]

Looking good. Cheers.

[makinezmoney]

$ACON: And there she goessssssss......... now 0.70


Wuzzupppppppppppppppppppp


GO $ACON

[Nealio]

Any Conference Call?? Quarterly out, looks promising; unclear about Mgmt direction; key events. Anyone have any insight about how Revenue will increase? When will it start increasing? What is the plan? Key upcoming events?

[Bronk]

Looking like it

[dinogreeves]

ACON will see 2-3 by end of the week.

[doogdilinger]

Friggin' fantastic news subs buddy!!!!!!!!!!!!!

[subslover]

$ACON is now totally NASDAQ compliant. How are you ME Doogi?

[doogdilinger]

Nice low vol dippage ahead of the next accumulation wave rippage! Best of cont'd success everyone>>>$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$

[lowercaseBACON]

$150ish BIllion $$$ segment Oh yeah!!!

[lowercaseBACON]

Nociscan is a back/neck pain GAME CHANGER $$$

[Golden Cross]

solid day here

[lowercaseBACON]

Very heavy accumulation. Very good sign!

[lowercaseBACON]

lowercase b- ACON is nibbling!!!

[doogdilinger]

Agreeeeeeeeeeeeeed brotha!!!